Patents Examined by Rita J. Desai
  • Patent number: 11267814
    Abstract: In one aspect, the invention provides compounds of Formula I, and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula II, or Formula III. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease and cancer, using a compound of Formula I, Formula II, or Formula III.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: March 8, 2022
    Inventors: Debra Ellies, Jean-Philippe Rey, F. Scott Kimball
  • Patent number: 11248012
    Abstract: The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: February 15, 2022
    Assignee: GLAXO SMIIHKLINE BIOLOGICALS SA
    Inventors: Helene G. Bazin-Lee, Laura S. Bess, David A. Johnson
  • Patent number: 11242341
    Abstract: Solid state forms of Valbenazine, Valbenazine salts, processes for preparation thereof and pharmaceutical compositions thereof are disclosed. Processes for the preparation of Valbenazine and intermediates in the preparation thereof are further described.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: February 8, 2022
    Assignee: ASSIA CHEMICAL INDUSTRIES LTD.
    Inventors: Ariel Mittelman, Sharona Shachan-Tov, Abed Masarwa, Rotem Sella-Erez, Jonathan Enav, Motti Erlich, Victoria Machtey, Maytal Piran, Marina Yarovoy, Sagit Azran, Einat Kisin-Finfer, Tamar Nidam
  • Patent number: 11225472
    Abstract: The present invention relates to the compounds according to Formula (I), the racemates, enantiomers, diastereomers thereof or pharmaceutical acceptable salts thereof, or pharmaceutical compositions comprising these, for the treatment or prevention of metabolic disorders. The compounds according to Formula (I) are, as GPR40 agonists, available for oral administration with glucose-dependent insulin secretion mechanism, which exhibit excellent glucose lowering efficacy without the risk of hypoglycemia. Thus, the compounds and/or pharmaceutical compositions comprising the compounds as effective components are useful in treating and/or preventing symptoms of type 2 diabetes through adequate control of blood glucose.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: January 18, 2022
    Inventors: Jae-Hoon Kang, Hong-Sub Lee, Kyung-Mi An, Chang-Hee Hong, Hyun-Jung Kwak, Shuo-Lin Cui, Hyo-Jung Song
  • Patent number: 11214553
    Abstract: Disclosed is a method for preparing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) of formula (II), comprising the following steps: carrying out an alkylation reaction on cyclen in formula (I) and XCH2COOR in the presence of an acid-binding agent in water; adjusting a pH value to separate out a crude product of DOTA; and recrystallizing. The preparation method of the present invention is applicable to large-scale industrial production of DOTA, the whole process does not need to adopt an ion-exchange resin or low-temperature refrigeration mode for purification, and the purity and yield of the product are higher.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: January 4, 2022
    Assignee: VIWIT PHARMACEUTICAL CO., LTD.
    Inventors: Zhoujun Meng, Yigang He, Yanjun Wei, Yanping Xing
  • Patent number: 11214577
    Abstract: The present invention related to novel morphinans, compositions comprising the novel morphinans, and their uses as agonists of the kappa opioid receptor.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: January 4, 2022
    Assignee: Humanwell Pharmaceutical US
    Inventors: Subo Liao, Jun Yang, Jie Li, Wentao Du, Lie Li, Jinliang Lv, Zongquan Liao, Hao Zhou, Tianpeng Xie, Jianbo Yu
  • Patent number: 11203586
    Abstract: An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: December 21, 2021
    Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.
    Inventors: Li Zhu, Yanqing Yang, Liguang Dai, Xiaowei Duan, Zhao Yang, Hui Zhang, Yuandong Hu, Yong Peng, Yongxin Han, Rui Zhao, Xin Tian, Shanchun Wang
  • Patent number: 11203595
    Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: December 21, 2021
    Assignee: NOVARTIS AG
    Inventors: Badry Bursulaya, Andreas Fisch, James Paul Lajiness, Rainer Machauer, Swapnil Malekar, Hank Michael James Petrassi, Farshad Ramazani, Anne-Catherine Remond, Thomas Ullrich, Peggy Usselmann, Eric Vangrevelinghe
  • Patent number: 11192864
    Abstract: Disclosed is a method for producing calcobutrol used as an MRI contrast agent. The method comprises the steps of: obtaining butrol represented by chemical formula 2 in the specification by reacting a gadobutrol represented by chemical formula 1 in the specification and a decomplexing agent; and obtaining a calcobutrol represented by chemical Formula 3 in the specification by reacting butrol with calcium ions.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: December 7, 2021
    Assignee: ENZYCHEM LIFESCIENCES CORPORATION
    Inventors: Jae Yong Lee, Jong Soo Lee, Byung Kyu Kang, Byuong Woo Lee, Sang Oh Lee, Dae Myoung Yun, Jae Hun Bang, Ki Young Sohn
  • Patent number: 11191769
    Abstract: The present disclosure provides compounds that modulate protein function, to restore protein homeostasis, and cell-cell adhesion. The disclosure provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, are provided.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: December 7, 2021
    Assignee: BioTheryX, Inc.
    Inventors: Kyle W. H. Chan, Aparajita Hoskote Chourasia, Paul E. Erdman, Leah Fung, Frank Mercurio, Robert Sullivan
  • Patent number: 11180455
    Abstract: Provided herein are compounds that are useful in the treatment of pain in a subject.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: November 23, 2021
    Inventors: Thomas Andrew Wynn, Juan C. Alvarez, Demetri Theodore Moustakas, Markus Haeberlein, Lewis D. Pennington
  • Patent number: 11179376
    Abstract: The present invention provides salts of pyrazolo[1,5-?]pyridine derivative and use thereof. The invention also relates to a pharmaceutically acceptable composition comprising such salts and a method of using the salts and the pharmaceutically acceptable composition to prevent or treat a proliferative disorder or pulmonary fibrosis in a patient.
    Type: Grant
    Filed: December 15, 2018
    Date of Patent: November 23, 2021
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Mingming Sun
  • Patent number: 11168097
    Abstract: The present technology relates generally cyclobutane boronates, including methods of preparation by exposing a mixture of a compound of Formula I in a solvent and a catalytic amount of a visible light sensitizer to provide a compound of Formula II, stereoisomers thereof, and/or salts of any of the foregoing. The cyclobutane boronate compounds are useful intermediates in the preparation of pharmaceutically active compounds as well as other useful compounds.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 9, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Tehshik Peter Yoon, Spencer Owen Scholz, Rowan Mark Littlefield, Niecia Elizabeth Flikweert
  • Patent number: 11161818
    Abstract: A novel quinolone derivative and methods of its preparation are described in which the novel derivative comprises a diphenyl ether substituent on the nitrogen atom at the 1-position of the main quinolone ring. The novel derivative is shown to have antibacterial and anti-tumor cell activity.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: November 2, 2021
    Assignee: HANGZHOU NORMAL UNIVERSITY
    Inventors: Pengfei Zhang, Wanmei Li, Weiming Xu, Haifeng Wu
  • Patent number: 11149017
    Abstract: Disclosed are solid state forms of Apalutamide and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: October 19, 2021
    Assignee: WATSON LABORATORIES INC.
    Inventors: Anantha Rajmohan Muthusamy, Sundara Lakshmi Kanniah, Nitin Dnyaneshwar Arote, Omkar Vilas Bhagwat, Jitendra Kamalakar Sonar, Vitthal Baburao Poundkar, Yogesh Dhananjay Wagh
  • Patent number: 11142503
    Abstract: The invention provides (1) processes for making substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives; (2) compositions useful in making substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives; and (3) methods of treating or preventing neurological disorders using substantially-pure (?) huperzine A and substantially-pure (?) huperzine A derivatives.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: October 12, 2021
    Assignee: YALE UNIVERSITY
    Inventors: Seth Herzon, Maung Kyaw Moe Tun
  • Patent number: 11135206
    Abstract: The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota ?-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: October 5, 2021
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yeh-Long Chen, Tian-Lu Cheng, Cherng-Chyi Tzeng, Chih-Hua Tseng, Ta-Chun Cheng, Kai-Wen Cheng, Wei-Fen Luo
  • Patent number: 11098071
    Abstract: The present invention relates to a GPR84 receptor antagonist and use thereof. The GPR84 receptor antagonist of the present invention has a structure as represented by formula (I), the definitions of R1, R2, R3, R4, L1, L2, L3, L4, L5, L6, Y, Z, and rings A, B, C, and D are as described in the description and claims. The GPR84 receptor antagonist of the present invention can competitively inhibit the activation of the receptor caused by an agonist of GPR84, and can be used in the preparation of a medicament for treating related diseases caused by high expression or high excitability of GPR84 receptor, the diseases including multiple sclerosis, inflammatory bowel disease, arthritis and the like.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 24, 2021
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Xin Xie, Linhai Chen, Qing Zhang, Yufeng Xiao, Hui Yang
  • Patent number: 11096930
    Abstract: Disclosed herein are substituted imidazopyridine compounds of formula (I) which are inhibitors of indoleamine 2,3-dioxygenase (IDO) and/or tryptophan-2,3-dioxygenase (TDO) enzymes: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO- and/or TDO-associated disease or disorder.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: August 24, 2021
    Assignees: Merck Sharp & Dohme Corp., IOmet Pharma Ltd.
    Inventors: Phillip M. Cowley, Meredeth Ann McGowan, Thomas J. Brown, Yongxin Han, Kun Liu, Qinglin Pu, Alan Wise, Hongjun Zhang, Hua Zhou
  • Patent number: 11098052
    Abstract: The present disclosure relates to 4-azapodophylotoxins compounds, pharmaceutical compositions comprising such compounds, kits, and methods for using such compounds or pharmaceutical compositions.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: August 24, 2021
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventor: George Robert Pettit